Development of a core outcome set for basal cell carcinoma
Title
Development of a core outcome set for basal cell carcinoma
Creator
Daniel I Schlessinger
Kelly A Reynolds
McKenzie A Dirr
Sarah A Ibrahim
Arianna F Yanes
Jake M Lazaroff
Victoria Godinez-Puig
Brian R Chen
Anastasia O Kurta
Jill K Cotseones
Sarah G Chiren
Karina C Furlan
Sanjana Iyengar
Ramona Behshad
Danielle M DeHoratius
Pablo Denes
Aaron M Drucker
Leonard M Dzubow
Jeremy R Etzkorn
Catherine A Harwood
John Y S Kim
Naomi Lawrence
Erica H Lee
Gary S Lissner
Ashfaq A Marghoob
Rubeta N Matin
Adam R Mattox
Bharat B Mittal
J Regan Thomas
Xiaolong Alan Zhou
David Zloty
Jochen Schmitt
Jamie J Kirkham
April W Armstrong
Nicole Basset-Seguin
Elizabeth M Billingsley
Jeremy S Bordeaux
Jerry Brewer
Marc Brown
Mariah Brown
Scott A B Collins
Maria Concetta Fargnoli
Sergio Jobim De Azevedo
Reinhard Dummer
Alexander Eggermont
Glenn D Goldman
Merete Haedersdal
Elizabeth K Hale
Allison Hanlon
Kelly L Harms
Conway C Huang
Eva A Hurst
Gino K In
Nicole Kelleners-Smeets
Meenal Kheterpal
Barry Leshin
Michel Mcdonald
Stanley J Miller
Alexander Miller
Eliot N Mostow
Myrto Trakatelli
Kishwer S Nehal
Desiree Ratner
Howard Rogers
Kavita Y Sarin
Seaver L Soon
Thomas Stasko
Paul A Storrs
Luca Tagliaferri
Allison T Vidimos
Sandra L Wong
Siegrid S Yu
Iris Zalaudek
Nathalie C Zeitouni
John A Zitelli
Emily Poon
Joseph F Sobanko
Todd V Cartee
Ian A Maher
Murad Alam
Date
2022
Description
Background: There is variation in the outcomes reported in clinical studies of basal cell carcinoma. This can prevent effective meta-analyses from answering important clinical questions.
Objective: To identify a recommended minimum set of core outcomes for basal cell carcinoma clinical trials.
Methods: Patient and professional Delphi process to cull a long list, culminating in a consensus meeting. To be provisionally accepted, outcomes needed to be deemed important (score, 7-9, with 9 being the maximum) by 70% of each stakeholder group.
Results: Two hundred thirty-five candidate outcomes identified via a systematic literature review and survey of key stakeholders were reduced to 74 that were rated by 100 health care professionals and patients in 2 Delphi rounds. Twenty-seven outcomes were provisionally accepted. The final core set of 5 agreed-upon outcomes after the consensus meeting included complete response; persistent or serious adverse events; recurrence-free survival; quality of life; and patient satisfaction, including cosmetic outcome.
Limitations: English-speaking patients and professionals rated outcomes extracted from English language studies.
Conclusion: A core outcome set for basal cell carcinoma has been developed. The use of relevant measures may improve the utility of clinical research and the quality of therapeutic guidance available to clinicians.
Objective: To identify a recommended minimum set of core outcomes for basal cell carcinoma clinical trials.
Methods: Patient and professional Delphi process to cull a long list, culminating in a consensus meeting. To be provisionally accepted, outcomes needed to be deemed important (score, 7-9, with 9 being the maximum) by 70% of each stakeholder group.
Results: Two hundred thirty-five candidate outcomes identified via a systematic literature review and survey of key stakeholders were reduced to 74 that were rated by 100 health care professionals and patients in 2 Delphi rounds. Twenty-seven outcomes were provisionally accepted. The final core set of 5 agreed-upon outcomes after the consensus meeting included complete response; persistent or serious adverse events; recurrence-free survival; quality of life; and patient satisfaction, including cosmetic outcome.
Limitations: English-speaking patients and professionals rated outcomes extracted from English language studies.
Conclusion: A core outcome set for basal cell carcinoma has been developed. The use of relevant measures may improve the utility of clinical research and the quality of therapeutic guidance available to clinicians.
Source
J Am Acad Dermatol
. 2022 Sep;87(3):573-581. doi: 10.1016/j.jaad.2022.04.059. Epub 2022 May 10.
. 2022 Sep;87(3):573-581. doi: 10.1016/j.jaad.2022.04.059. Epub 2022 May 10.
Language
English
URL
https://doi.org/10.1016/j.jaad.2022.04.059
Citation
Daniel I Schlessinger et al., “Development of a core outcome set for basal cell carcinoma,” NEOMED Bibliography Database, accessed April 26, 2024, https://neomed.omeka.net/items/show/12051.